1043890-93-2

Upstream product

• 1043890-92-1 (R)-3-((R)-6-(4-fluoro-3-methylbenzyloxy)-2-azidohexanoyl)-4-benzyloxazolidin-2-one 
• 502-44-3 hexahydro-2H-oxepin-2-one 
• 1043453-91-3 6-(4-fluoro-3-methylbenzyloxy)hexanoic acid 
• 261951-70-6 4-(bromomethyl)-1-fluoro-2-methylbenzene 
• 1043453-92-4 (R)-3-(6-(4-fluoro-3-methylbenzyloxy)hexanoyl)-4-benzyloxazolidin-2-one 

Downstream Products

• 1043890-94-3 (R)-methyl 6-(4-fluoro-3-methylbenzyloxy)-2-azidohexanoate 
• 1043890-81-8 (R)-2-(4-fluoro-3,5-dimethylphenylamino)-6-(4-fluoro-3-methylbenzyloxy)-N-hydroxyhexanamide 
• 1043890-95-4 (R)-methyl 6-(4-fluoro-3-methylbenzyloxy)-2-aminohexanoate 
• 1043890-96-5 (R)-methyl 2-(4-fluoro-3,5-dimethylphenylamino)-6-(4-fluoro-3-methylbenzyloxy)hexanoate 

Relevant academic research and scientific papers

Antidotes to anthrax lethal factor intoxication. Part 2: Structural modifications leading to improved in vivo efficacy

New anthrax lethal factor inhibitors (LFIs) were designed based upon previously identified potent inhibitors 1a and 2. Combining the new core structures with modifications to the C2-side chain yielded analogs with improved efficacy in the rat lethal toxin model.

HYDROXAMIC ACID DERIVATIVES OF ANILINE USEFUL AS THERAPEUTIC AGENTS FOR TREATING ANTHRAX POISONING

Compounds having the formula (I), wherein the symbols have the meaning described in the specification are hydroxamic acid derivatives of aniline and capable of inhibiting the lethal effects of infection by anthrax bacteria and are useful in the treatment of poisoning by anthrax.